680 related articles for article (PubMed ID: 15028476)
21. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
22. Expression of p27 and its ubiquitin ligase subunit Skp2 in upper urinary tract transitional cell carcinoma.
Langner C; von Wasielewski R; Ratschek M; Rehak P; Zigeuner R
Urology; 2004 Sep; 64(3):611-6. PubMed ID: 15351619
[TBL] [Abstract][Full Text] [Related]
23. Angiogenesis in vestibular schwannomas: expression of extracellular matrix factors MMP-2, MMP-9, and TIMP-1.
Møller MN; Werther K; Nalla A; Stangerup SE; Thomsen J; Bøg-Hansen TC; Nielsen HJ; Cayé-Thomasen P
Laryngoscope; 2010 Apr; 120(4):657-62. PubMed ID: 20205165
[TBL] [Abstract][Full Text] [Related]
24. Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract.
Miyata Y; Kanda S; Nomata K; Eguchi J; Kanetake H
J Urol; 2005 Jan; 173(1):56-60. PubMed ID: 15592025
[TBL] [Abstract][Full Text] [Related]
25. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
26. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis.
Arnold SM; Young AB; Munn RK; Patchell RA; Nanayakkara N; Markesbery WR
Clin Cancer Res; 1999 Dec; 5(12):4028-33. PubMed ID: 10632335
[TBL] [Abstract][Full Text] [Related]
27. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role.
Miyata Y; Iwata T; Maruta S; Kanda S; Nishikido M; Koga S; Kanetake H
Eur Urol; 2007 Sep; 52(3):791-7. PubMed ID: 17207914
[TBL] [Abstract][Full Text] [Related]
28. Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis.
Miyata Y; Kanda S; Ohba K; Nomata K; Eguchi J; Hayashida Y; Kanetake H
J Urol; 2006 Jul; 176(1):348-53. PubMed ID: 16753442
[TBL] [Abstract][Full Text] [Related]
29. [The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival].
Fontana LO; García García F; Arcas Martínez Salas I; García Ligero J; Tomás Ros M; Rico Galiano JL; Sempere Gutiérrez A; Canteras Jordana M
Arch Esp Urol; 2002 Sep; 55(7):792-6. PubMed ID: 12380307
[TBL] [Abstract][Full Text] [Related]
30. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
31. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer.
Kanayama H; Yokota K; Kurokawa Y; Murakami Y; Nishitani M; Kagawa S
Cancer; 1998 Apr; 82(7):1359-66. PubMed ID: 9529029
[TBL] [Abstract][Full Text] [Related]
32. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
33. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
34. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
35. Matrix metalloproteinase production by bone marrow mononuclear cells from normal individuals and patients with acute and chronic myeloid leukemia or myelodysplastic syndromes.
Ries C; Loher F; Zang C; Ismair MG; Petrides PE
Clin Cancer Res; 1999 May; 5(5):1115-24. PubMed ID: 10353746
[TBL] [Abstract][Full Text] [Related]
36. Expression of matrix metalloproteinase-7 on cancer cells and tissue endothelial cells in renal cell carcinoma: prognostic implications and clinical significance for invasion and metastasis.
Miyata Y; Iwata T; Ohba K; Kanda S; Nishikido M; Kanetake H
Clin Cancer Res; 2006 Dec; 12(23):6998-7003. PubMed ID: 17145820
[TBL] [Abstract][Full Text] [Related]
37. Postoperative radiation therapy in 26 patients with invasive transitional cell carcinoma of the upper urinary tract: no impact on survival?
Maulard-Durdux C; Dufour B; Hennequin C; Chrétien Y; Vignes B; Droz D; Delanian S; Housset M
J Urol; 1996 Jan; 155(1):115-7. PubMed ID: 7490805
[TBL] [Abstract][Full Text] [Related]
38. Location of the primary tumor is not an independent predictor of cancer specific mortality in patients with upper urinary tract urothelial carcinoma.
Isbarn H; Jeldres C; Shariat SF; Liberman D; Sun M; Lughezzani G; Widmer H; Arjane P; Pharand D; Fisch M; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
J Urol; 2009 Nov; 182(5):2177-81. PubMed ID: 19758662
[TBL] [Abstract][Full Text] [Related]
39. [Relationship between bFGF mRNA and MMP-9 mRNA expression in gastric carcinoma and their clinicopathological features as well as patients survival].
Zhao ZS; Yao GY; Ru GQ; Ma J; Ruan J
Zhonghua Wai Ke Za Zhi; 2005 Feb; 43(3):169-72. PubMed ID: 15842896
[TBL] [Abstract][Full Text] [Related]
40. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
